% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • cabos_tacos cabos_tacos May 4, 2013 10:32 AM Flag


    VRTX can kiss 300+million a year goodbye sooner than later......

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ...and next year Vertex will be able to provide 'breakthrough' treatment for the majority of CF patients:

      S&P analyst's remarks on May 1: ".We remain
      confident in VRTX's cystic fibrosis program, with key F508del mutation sub-group
      on track for '14 FDA filing. "

      Count on expdited approval by the FDA in 2014 to treat close to twenty thousand CF patients in the US alone. That's multibillion dollar a year market. so 300 million of lost Incivek revenue won't be a huge problem going forward, and VX 135 will likely generate far more in the years to come. Then factor in the poetential for VX 509, 787, 661 983, and the second gneration correctors for treating the 508d heterozygotes with CF, and the future for Vertex is amazing.

      • 2 Replies to qdelfan
      • "Next Year....." But in the meantime the rent, electric bills, and all those excised stock options keep coming in.......
        300mil of actual income a year paid a lot of bills .......

      • Q, I agree. Although am somewhat disappointed that there has been very little from vertex on doing anything with 787 and 509. They are too big for vertex to own the trials and they pretty much said that while the molecules look good, they need to partner to move them along. That was quite a while ago and it has been crickets since. Also, I knew 222 was dead. They had not mentioned it for a while and finally took the write down last quarter. When they don't mention anything for a while it is a bad sign.

79.47-1.29(-1.60%)11:56 AMEDT